Since SGLT2 inhibitors showed improvement of multiple CV risk factors in addition to hyperglycemia in preclinical studies, treatment with SGLT2 inhibitors had been expected to reduce the risk of CV events. Here, SLC5A2 is linked to Hyperglycemia.